ZA919750B - Medicaments - Google Patents

Medicaments

Info

Publication number
ZA919750B
ZA919750B ZA919750A ZA919750A ZA919750B ZA 919750 B ZA919750 B ZA 919750B ZA 919750 A ZA919750 A ZA 919750A ZA 919750 A ZA919750 A ZA 919750A ZA 919750 B ZA919750 B ZA 919750B
Authority
ZA
South Africa
Prior art keywords
medicaments
Prior art date
Application number
ZA919750A
Other languages
English (en)
Inventor
Joanne Craig
Craig Joanne
Derek Leslie Crookes
Leslie Crookes Derek
Stephen John Skittrall
John Skittrall Stephen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA919750B publication Critical patent/ZA919750B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
ZA919750A 1990-12-12 1991-12-11 Medicaments ZA919750B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (1)

Publication Number Publication Date
ZA919750B true ZA919750B (en) 1992-10-28

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA919750A ZA919750B (en) 1990-12-12 1991-12-11 Medicaments

Country Status (36)

Country Link
US (2) US5554639A (enExample)
EP (1) EP0490689B1 (enExample)
JP (1) JP2994037B2 (enExample)
KR (1) KR100211479B1 (enExample)
CN (2) CN1030890C (enExample)
AP (1) AP230A (enExample)
AT (1) ATE119881T1 (enExample)
AU (1) AU650706B2 (enExample)
BE (1) BE1005085A3 (enExample)
CA (1) CA2098302C (enExample)
CH (1) CH684192A5 (enExample)
CY (1) CY2005A (enExample)
CZ (1) CZ281931B6 (enExample)
DE (1) DE69108200T2 (enExample)
DK (1) DK0490689T3 (enExample)
EG (1) EG20219A (enExample)
ES (1) ES2069836T3 (enExample)
FR (1) FR2670487B1 (enExample)
GB (2) GB9026998D0 (enExample)
GR (1) GR3015430T3 (enExample)
HK (1) HK82697A (enExample)
HU (1) HU211937A9 (enExample)
IE (1) IE62894B1 (enExample)
IL (1) IL100330A (enExample)
IS (1) IS1706B (enExample)
IT (1) IT1252868B (enExample)
MX (1) MX9102501A (enExample)
MY (1) MY109265A (enExample)
NL (1) NL9102071A (enExample)
NZ (1) NZ240942A (enExample)
PT (1) PT99757B (enExample)
RU (1) RU2108328C1 (enExample)
TW (2) TW205035B (enExample)
WO (1) WO1992010477A1 (enExample)
YU (1) YU48926B (enExample)
ZA (1) ZA919750B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116411T3 (es) * 1992-06-05 1998-07-16 Merck Sharp & Dohme La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
ATE404193T1 (de) * 2001-06-05 2008-08-15 Ronald Aung-Din Topische migränetherapie
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
SI1575566T1 (sl) * 2002-12-26 2012-08-31 Pozen Inc Veäśplastna dozirna oblika vsebujoäśa naproksen in triptane
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CN102046621B (zh) 2008-05-27 2014-11-12 生物区科学管理控股有限公司 抗病毒盐
EP2306998A4 (en) * 2008-06-20 2011-06-15 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
EP2296652B1 (en) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
EP3294339B1 (en) 2015-05-15 2020-12-02 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
MX2020004566A (es) 2017-11-07 2020-08-13 Univ Michigan Regents Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
AU2021227937A1 (en) * 2020-02-27 2022-09-08 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
RU2108328C1 (ru) 1998-04-10
DE69108200D1 (de) 1995-04-20
DK0490689T3 (da) 1995-05-22
KR100211479B1 (ko) 1999-08-02
ATE119881T1 (de) 1995-04-15
EP0490689A1 (en) 1992-06-17
NL9102071A (nl) 1992-07-01
CN1063099A (zh) 1992-07-29
CN1128259A (zh) 1996-08-07
TW205035B (enExample) 1993-05-01
IE914317A1 (en) 1992-06-17
AP9100339A0 (en) 1992-01-31
GR3015430T3 (en) 1995-06-30
CA2098302C (en) 2001-10-16
HU211937A9 (en) 1996-01-29
YU48926B (sh) 2002-12-10
GB2251614B (en) 1994-12-14
CZ281931B6 (cs) 1997-04-16
IE62894B1 (en) 1995-03-08
CA2098302A1 (en) 1992-06-13
PT99757B (pt) 1999-05-31
IT1252868B (it) 1995-06-28
CN1050831C (zh) 2000-03-29
JPH06503560A (ja) 1994-04-21
AU650706B2 (en) 1994-06-30
CH684192A5 (fr) 1994-07-29
JP2994037B2 (ja) 1999-12-27
IL100330A (en) 1996-06-18
PT99757A (pt) 1992-12-31
GB9126297D0 (en) 1992-02-12
GB9026998D0 (en) 1991-01-30
IS1706B (is) 1998-12-10
NZ240942A (en) 1994-03-25
MX9102501A (es) 1992-09-01
AP230A (en) 1993-01-27
TW300886B (enExample) 1997-03-21
FR2670487B1 (fr) 1993-08-20
AU9072091A (en) 1992-07-08
US5554639A (en) 1996-09-10
GB2251614A (en) 1992-07-15
BE1005085A3 (fr) 1993-04-13
CY2005A (en) 1997-12-05
HK82697A (en) 1997-06-27
DE69108200T2 (de) 1995-07-20
ES2069836T3 (es) 1995-05-16
FR2670487A1 (fr) 1992-06-19
YU191491A (sh) 1994-04-05
IS3790A7 (is) 1992-06-13
US5705520A (en) 1998-01-06
ITRM910922A0 (it) 1991-12-11
IL100330A0 (en) 1992-09-06
CN1030890C (zh) 1996-02-07
EP0490689B1 (en) 1995-03-15
CZ114093A3 (en) 1994-02-16
MY109265A (en) 1996-12-31
EG20219A (en) 1997-11-30
WO1992010477A1 (en) 1992-06-25
ITRM910922A1 (it) 1993-06-11

Similar Documents

Publication Publication Date Title
GB9026998D0 (en) Medicaments
GB9012469D0 (en) Medicaments
CY2134B1 (en) Medicaments
AP9200403A0 (en) Medicaments
GB9027211D0 (en) Medicaments
GB9027210D0 (en) Medicaments
GB9027200D0 (en) Medicaments
GB9027199D0 (en) Medicaments
GB9027212D0 (en) Medicaments
GB9027208D0 (en) Medicaments
GB9027198D0 (en) Medicaments
GB9027197D0 (en) Medicaments
GB9027209D0 (en) Medicaments
GB9027201D0 (en) Medicaments
GB9104650D0 (en) Medicaments
GB9108348D0 (en) Medicaments
GB9016950D0 (en) Medicaments
GB9022016D0 (en) Medicaments
GB9009067D0 (en) Medicaments
GB9004015D0 (en) Medicaments
GB9010366D0 (en) Medicaments
GB9011940D0 (en) Medicaments
GB9013265D0 (en) Medicaments
GB9013266D0 (en) Medicaments
GB9016612D0 (en) Medicaments